Homepage Top Section1

Ultomiris is said to be the first and only long-acting C5 inhibitor administered every eight weeks and it works by inhibiting the C5 protein in the terminal complement

Victoza was approved by the regulator for the treatment of type 2 diabetes in adult patients in 2010. It is now the first non-insulin drug to be approved

The Dialize trial has evaluated the efficacy and safety of Lokelma to treat hyperkalaemia, which is a serious condition indicated by elevated potassium levels in the blood. According

The acquisition of Medidata will help Dassault to create its first end-to-end scientific and business platform for life sciences industry. As per terms of the deal, Dassault will

The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the

The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-free survival (PFS). The combination therapy, which was administered for a

The Kisqali combination therapy, which was evaluated in both pre- and perimenopausal women in the late-stage trial called MONALEESA-7, delivered statistically significant overall survival (OS) results in comparison

CNTX-0290 is a small molecule somatostatin receptor type 4 (SSTR4) agonist, which is being evaluated for the treatment of chronic pain conditions in a phase 1 clinical trial.

The FDA has approved Piqray kinase inhibitor in combination with fulvestrant to treat postmenopausal women, and men with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-),